Next Article in Journal
Colorectal Cancer Stem Cells and Cell Death
Next Article in Special Issue
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
Previous Article in Journal / Special Issue
Recent Advance in Biosensors for microRNAs Detection in Cancer
Cancers 2011, 3(2), 1899-1928; doi:10.3390/cancers3021899
Review

Neuropilins: A New Target for Cancer Therapy

1,2,3,*  and 1,2,3,4
Received: 23 February 2011; in revised form: 23 March 2011 / Accepted: 1 April 2011 / Published: 8 April 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
View Full-Text   |   Download PDF [444 KB, updated 9 May 2011; original version uploaded 8 April 2011]   |   Browse Figures
Abstract: Recent investigations highlighted strong similarities between neural crest migration during embryogenesis and metastatic processes. Indeed, some families of axon guidance molecules were also reported to participate in cancer invasion: plexins/semaphorins/neuropilins, ephrins/Eph receptors, netrin/DCC/UNC5. Neuropilins (NRPs) are transmembrane non tyrosine-kinase glycoproteins first identified as receptors for class-3 semaphorins. They are particularly involved in neural crest migration and axonal growth during development of the nervous system. Since many types of tumor and endothelial cells express NRP receptors, various soluble molecules were also found to interact with these receptors to modulate cancer progression. Among them, angiogenic factors belonging to the Vascular Endothelial Growth Factor (VEGF) family seem to be responsible for NRP-related angiogenesis. Because NRPs expression is often upregulated in cancer tissues and correlated with poor prognosis, NRPs expression might be considered as a prognostic factor. While NRP1 was intensively studied for many years and identified as an attractive angiogenesis target for cancer therapy, the NRP2 signaling pathway has just recently been studied. Although NRP genes share 44% homology, differences in their expression patterns, ligands specificities and signaling pathways were observed. Indeed, NRP2 may regulate tumor progression by several concurrent mechanisms, not only angiogenesis but lymphangiogenesis, epithelial-mesenchymal transition and metastasis. In view of their multiples functions in cancer promotion, NRPs fulfill all the criteria of a therapeutic target for innovative anti-tumor therapies. This review focuses on NRP-specific roles in tumor progression.
Keywords: neuropilins; cancer; angiogenesis; lymphangiogenesis; targeted therapies neuropilins; cancer; angiogenesis; lymphangiogenesis; targeted therapies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Grandclement, C.; Borg, C. Neuropilins: A New Target for Cancer Therapy. Cancers 2011, 3, 1899-1928.

AMA Style

Grandclement C, Borg C. Neuropilins: A New Target for Cancer Therapy. Cancers. 2011; 3(2):1899-1928.

Chicago/Turabian Style

Grandclement, Camille; Borg, Christophe. 2011. "Neuropilins: A New Target for Cancer Therapy." Cancers 3, no. 2: 1899-1928.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert